About gemcitabine hydrochloride eq to gemcitabine
Antineoplastic nucleoside analogue
Used for
- Pancreatic cancer
- Non-small cell lung cancer
- Ovarian cancer
- Breast cancer
Usual adult dose
Cancer-specific intravenous schedules vary; commonly 1,000–1,250 mg/m² on scheduled treatment days.
Common side effects
- Low blood-cell counts
- Nausea and vomiting
- Fatigue
- Rash or hair loss
Important warnings
- Can cause severe bone-marrow suppression and infection or bleeding.
- Rarely causes serious lung, liver, kidney, or blood-vessel complications.
- Treatment requires specialist supervision and blood-test monitoring.
- Avoid live vaccines during treatment.
Pregnancy
May harm an unborn baby; generally avoid during pregnancy. Effective contraception is recommended during treatment.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least one week after the last dose.
Interactions
- Radiotherapy may increase tissue toxicity.
- Other medicines that suppress bone marrow may increase blood-count problems.
- Warfarin may require closer monitoring.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.